Phathom Pharmaceuticals Overview
- Founded
-
2018

- Status
-
Public
- Employees
-
97

- Stock Symbol
-
PHAT

- Share Price
-
$12.00
- (As of Thursday Closing)
Phathom Pharmaceuticals General Information
Description
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Contact Information
- 100 Campus Drive
- Suite 102
- Florham Park, NJ 07932
- United States
Phathom Pharmaceuticals Timeline
Phathom Pharmaceuticals Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$12.00 | $11.72 | $6.09 - $19.95 | $499M | 41.6M | 258K | -$4.67 |
Phathom Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 321,121 | 487,879 | 758,010 | 807,112 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (158,288) | (136,615) | (125,255) | (252,035) |
Net Income | (178,502) | (143,883) | (129,068) | (255,131) |
Total Assets | 201,931 | 189,431 | 295,111 | 257,178 |
Total Debt | 95,810 | 91,341 | 49,018 | 23,573 |
Phathom Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Phathom Pharmaceuticals Comparisons
Industry
Financing
Details
Phathom Pharmaceuticals Competitors (34)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000 - 000 | 00000 |
0000000 | Formerly VC-backed | Fremont, CA | 000 | 00000 | 000000 - 000 | 00000 |
000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
000000000000000 | Formerly VC-backed | Blacksburg, VA | 0 | 00000000000 | ||
0000000 | Formerly PE-Backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
Phathom Pharmaceuticals Executive Team (11)
Phathom Pharmaceuticals Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
David Socks | Self | Founder & Board Member | 000 0000 |
Frank Karbe | Self | Board Member | 000 0000 |
Heidi Kunz | Phathom Pharmaceuticals | Board Member | 000 0000 |
Mark Stenhouse | Self | Board Member | 000 0000 |
Michael Cola | Phathom Pharmaceuticals | Board Member | 000 0000 |
Phathom Pharmaceuticals Signals
Phathom Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Phathom Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 10, 2022
33.82 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Pharmaceuticals
Subindustry
00 of 473
Rank
Percentile
